{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:59:29Z","timestamp":1794887969620,"version":"4.9.1"},"reference-count":53,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The U.S. Food and Drug Administration approved three disease-modifying treatments for mild cognitive impairment and early Alzheimer\u2019s disease: aducanumab, lecanemab, and donanemab, which showed little efficacy, serious side effects, and are costly. Repetitive transcranial magnetic stimulation (rTMS) may overcome these difficulties by its safe, cheap, and potentially disease-modifying properties that extend beyond A\u03b2 removal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>We aim to compare the efficacy on cognitive function, tolerability, and acceptability of rTMS with aducanumab, lecanemab, and donanemab in people with mild cognitive impairment and Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically reviewed relevant randomized placebo-controlled trials in PubMed, the CENTRAL, the CINHAL, and the ClinicalTrials.gov and performed a random-effect network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Nineteen randomized placebo-controlled trials with 6918 participants were included. rTMS was significantly more effective than placebo\/sham stimulation. In addition, rTMS was significantly more effective than aducanumab, lecanemab, and donanemab. Furthermore, rTMS was not significantly inferior to placebo\/sham stimulation in tolerability and acceptability, whereas aducanumab, lecanemab, and donanemab were significantly inferior to placebo\/sham stimulation in tolerability and acceptability. rTMS was significantly superior to lecanemab and donanemab in acceptability. No significant differences were observed in the remaining comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>rTMS may be more effective, tolerable, and acceptable than aducanumab, lecanemab, and donanemab. Long-term direct comparison studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251340901","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:23:49Z","timestamp":1747635829000},"page":"1225-1231","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and network meta-analysis"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-5637","authenticated-orcid":false,"given":"Itsuki","family":"Terao","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Ikokoro Clinic Nihonbashi, Chuo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakako","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Yu Mental Clinic Ikebukuro, Toshima-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6128-4"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2017.03.007"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201500004"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/brain.2017.0509"},{"key":"e_1_3_3_7_1","first-page":"188","article-title":"Systematic review and meta-analysis confirm the moderate efficacy of high-frequency r-TMS in Alzheimer\u2019s disease: Mediating effects of anhedonia-apathy and add-on motor-cognitive excersizes","volume":"36","author":"Chigareva O","year":"2024","unstructured":"Chigareva O, Astafeva D, Bikbaeva K, et al. (2024) Systematic review and meta-analysis confirm the moderate efficacy of high-frequency r-TMS in Alzheimer\u2019s disease: Mediating effects of anhedonia-apathy and add-on motor-cognitive excersizes. Psychiatr Danub 36: 188\u2013202.","journal-title":"Psychiatr Danub"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.20110279"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.854733"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205704"},{"key":"e_1_3_3_11_1","unstructured":"Eisai (2021) Biogen announces reduced price for Aduhelm\u00ae to improve access for patients with early Alzheimer\u2019s disease in the United States. Available at: https:\/\/www.eisai.com\/news\/2021\/news2021100.html (accessed 4 April 2025)."},{"key":"e_1_3_3_12_1","unstructured":"Eisai (2023) Eisai\u2019s approach to U.S. Pricing For Leqembi\u2122 (Lecanemab) a treatment for early Alzheimer\u2019s disease sets forth our concept of \u201csocietal value of medicine\u201d in relation to \u201cprice of medicine.\u201d Available at: https:\/\/www.eisai.com\/news\/2023\/news202302.html (accessed 4 April 2025)."},{"key":"e_1_3_3_13_1","unstructured":"Eli Lilly and Company (2024) Lilly\u2019s Kisunla\u2122 (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer\u2019s disease. Available at: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early (accessed 4 April 2025)."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30217-2"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.11.014"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2016.1255353"},{"key":"e_1_3_3_17_1","first-page":"1","article-title":"Repetitive transcranial magnetic stimulation for treatment-resistant depression: An economic analysis","volume":"16","author":"Health Quality Ontario","year":"2016","unstructured":"Health Quality Ontario (2016) Repetitive transcranial magnetic stimulation for treatment-resistant depression: An economic analysis. Ont Health Technol Assess Ser 16: 1\u201351.","journal-title":"Ont Health Technol Assess Ser"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612820666140826114601"},{"key":"e_1_3_3_19_1","unstructured":"Higgins JPT Thomas J Chandler J et al. (2023) Cochrane handbook for systematic reviews of Interventions version 6.4 (updated August 2023). Available at: www.training.cochrane.org\/handbook"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105704"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/NRR.NRR-D-23-01201"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.593000"},{"key":"e_1_3_3_24_1","first-page":"803","article-title":"Indirect comparisons and network meta-analyses","volume":"112","author":"Kiefer C","year":"2015","unstructured":"Kiefer C, Sturtz S, Bender R (2015) Indirect comparisons and network meta-analyses. Dtsch Arztebl Int 112: 803\u2013808.","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716673321"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2022.114229"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2021.01.012"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150346"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.12.1475"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3018"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.862958"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2011.08.003"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells14020086"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.add9993"},{"key":"e_1_3_3_36_1","unstructured":"R Core Team (2022) R: A language and environment for statistical computing. Available at: https:\/\/www.R-project.org\/ (accessed 7 November 2024)."},{"key":"e_1_3_3_37_1","unstructured":"Rohatgi A (2022) WebPlotDigitizer. Available at: https:\/\/automeris.io\/WebPlotDigitizer (accessed 7 November 2024)."},{"key":"e_1_3_3_38_1","unstructured":"R\u00fccker G Krahn U K\u00f6nig J et al. (2022) netmeta: Network meta-analysis using frequentist methods. R package version 2.5-0. Available at: https:\/\/CRAN.R-project.org\/package=netmeta"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.12616"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.993306"},{"key":"e_1_3_3_41_1","article-title":"Vascular factors and Alzheimer disease","volume":"13","author":"Skoog I","year":"1999","unstructured":"Skoog I, Kalaria RN, Breteler MM (1999) Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 13: S106\u2013S114.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"e_1_3_3_42_1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomized trials. BMJ 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.jin2105140"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01520-y"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101709"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102203"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-230911"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101499"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-200286"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0001-x"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04245-4"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2022.06.004"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103891"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251340901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251340901","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251340901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:13Z","timestamp":1777507933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251340901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/02698811251340901"],"URL":"https:\/\/doi.org\/10.1177\/02698811251340901","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}